Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin
about
Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms.Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers.A neuroendocrine mechanism of co-morbidity of depression-like behavior and myocardial injury in rats.Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Prazosin, Terazosin, and Doxazosin in Pharmaceutical Formulations.Cardiovascular and ocular safety of α1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms.Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.A review of drug-drug interactions in older HIV-infected patients.Clinical pharmacology of functional disorders of the urogenital system.Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model.Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model.Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.
P2860
Q30249162-45C55D78-3A9B-44EA-8EA0-FA01CD7CBDC0Q34511634-E2823F9D-8694-47B1-B3F2-BAEF13D966EAQ35097384-E10367A7-D81B-4C2D-B1BE-9D590D738264Q36248988-E90C9FE5-E7DE-442F-9DA4-FBDD8A40481DQ38235157-66FAA88B-2905-4F3F-8C6A-8D66482C6632Q38743428-3ED6DABA-B8BF-486E-9E34-698CCECDF347Q41996857-AC6B74C7-C482-4934-9DC5-911F634C446BQ42876778-ADB6FAE2-5461-4A23-B707-6EF5EE9BE60DQ49140346-5C0D64A6-662E-437C-9923-0D103ECDF49DQ49345918-F5E614A9-BFF2-4D57-A22A-34DA993EDE73Q52637933-16B22694-D672-41E3-8BA8-78E9079197CA
P2860
Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Effects of strong CYP2D6 and 3 ...... ovascular safety of tamsulosin
@en
type
label
Effects of strong CYP2D6 and 3 ...... ovascular safety of tamsulosin
@en
prefLabel
Effects of strong CYP2D6 and 3 ...... ovascular safety of tamsulosin
@en
P2093
P2860
P1476
Effects of strong CYP2D6 and 3 ...... ovascular safety of tamsulosin
@en
P2093
Joachim Troost
Ludwig Mehlburger
Martin C Michel
Martina Wein
Michaela Mattheus
Shinji Tatami
Yasuhiro Tsuda
P2860
P304
P356
10.1111/J.1365-2125.2011.03988.X
P407
P577
2011-08-01T00:00:00Z